Elos Medtech - Year- end report for the period 1 January to 31 December, 2017
Higher sales in several market segments
Net sales for the financial year increased to SEK 577.9 (552.0) million, which corresponds to growth of 4.3 % after currency adjustments.
Operating profit amounted to SEK 42.7 (42.7) million.
Profit after net financial items amounted to SEK 26.4 (37.9) million. There was a negative impact of -7.2 (5.4) million on net financial items from exchange differences.
Profit after tax amounted to SEK 22.6 (26.4) million, corresponding to SEK 3.74 (4.37) per share.
Cash flow from operating activities was SEK 62.1 (98.3) million, and amounted to SEK 24.5 (68.9) million after investments.
On 19 February 2018, the Board of Directors made an authorized decision (granted at the extraordinary general meeting on 15 December) to approve a preferential rights issue of SEK 104.9 million before issue costs. The proceeds from the issue will be used for investments to increase production capacity.
Against the background of the new share issue, the Board of Directors proposes that no dividend be paid for the financial year 2017.
For further information, contact:
Jan Wahlström, President and CEO, +46 70-212 18 89, e-mail: email@example.com
Christian Bergaust, CFO, +46 70-293 50 40, e-mail: firstname.lastname@example.org
This is the type of information that Elos Medtech AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was issued for publication by the contact persons stated above on 19 February 2018, at 18:00 a.m. (CET).
For additional information about the Elos Medtech Group, visit www.elosmedtech.com